Novartis AG (SWX:NOVN)
94.19
-0.83 (-0.87%)
Jul 31, 2025, 5:34 PM CET
Longboard Pharmaceuticals Revenue
Novartis AG had revenue of $14.84B USD in the quarter ending June 30, 2025, with 15.26% growth. This brings the company's revenue in the last twelve months to $55.19B, up 12.95% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$55.19B
Revenue Growth
+12.95%
P/S Ratio
4.19
Revenue / Employee
$727.25K
Employees
75,883
Market Cap
183.94B
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Lonza Group AG | 7.09B |
Alcon | 8.77B |
Galderma Group AG | 3.73B |
Sandoz Group AG | 9.41B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.87B |
Ypsomed Holding AG | 748.87M |
Novartis AG News
- 1 day ago - Trump's pharmaceutical tariffs could affect some drugmakers more than others - CNBC
- 6 days ago - 3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs - Benzinga
- 7 days ago - Matchpoint in pact with Novartis for inflammatory disease treatments - Seeking Alpha
- 7 days ago - Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies - Reuters
- 7 days ago - Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases - GlobeNewsWire
- 10 days ago - Novartis AG 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 10 days ago - Novartis AG (NVS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price - Seeking Alpha